

Amendments to the Claims

Please cancel Claims 154, 166, 176, 186, 195, 247 and 258. Please amend Claims 151, 163, 175, 185, 194, 198, 204, 213, 217, 246, 257, 292, 296 and 355. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-150. (Canceled)

151. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

152. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES.

153. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.

154. (Canceled)

155. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

156. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11

(ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

157. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
158. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
159. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
160. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 151 and a physiologically acceptable vehicle or carrier.
161. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 151.
162. (Previously presented) The isolated cell of Claim 161, wherein said isolated cell is a hybridoma.
163. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

164. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES
165. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.
166. (Canceled)
167. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
168. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
169. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
170. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
171. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

172. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 163 and a physiologically acceptable vehicle or carrier.
173. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 163.
174. (Previously presented) The isolated cell of Claim 173, wherein said isolated cell is a hybridoma.
175. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
176. (Canceled)
177. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
178. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
179. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

180. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
181. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
182. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 175 and a physiologically acceptable vehicle or carrier.
183. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 175.
184. (Previously presented) The isolated cell of Claim 183, wherein said isolated cell is a hybridoma.
185. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for eotaxin.
186. (Canceled)
187. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein

comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

188. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
189. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
190. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
191. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 185 and a physiologically acceptable vehicle or carrier.
192. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 185.
193. (Previously presented) The isolated cell of Claim 192, wherein said isolated cell is a hybridoma.
194. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

195. (Canceled)
196. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
197. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
198. (Currently amended) The antibody or antigen-binding fragment of Claim 194, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
199. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
200. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
201. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 194 and a physiologically acceptable vehicle or carrier.
202. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 194.

203. (Previously presented) The isolated cell of Claim 202, wherein said isolated cell is a hybridoma.
204. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
205. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
206. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
207. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
208. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
209. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody,

an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

210. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 204 and a physiologically acceptable vehicle or carrier.
211. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 204.
212. (Previously presented) The isolated cell of Claim 211, wherein said isolated cell is a hybridoma.
213. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
214. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 213 and a physiologically acceptable vehicle or carrier.
215. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 213.
216. (Previously presented) The isolated cell of Claim 215, wherein said isolated cell is a hybridoma.
217. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.

218. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 217 and a physiologically acceptable vehicle or carrier.
219. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 217.
220. (Previously presented) The isolated cell of Claim 219, wherein said isolated cell is a hybridoma.
- 221-245. (Canceled)
246. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.
247. (Canceled)
248. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
249. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11

(ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

250. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
251. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
252. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
253. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
254. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 246 and a physiologically acceptable vehicle or carrier.
255. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 246.

256. (Previously presented) The isolated cell of Claim 255, wherein said isolated cell is a hybridoma.
257. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.
258. (Canceled)
259. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
260. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
261. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
262. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody,

an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

263. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
264. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 257 and a physiologically acceptable vehicle or carrier.
265. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 257.
266. (Previously presented) The isolated cell of Claim 265, wherein said isolated cell is a hybridoma.
- 267-291. (Canceled)
292. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.
293. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 292 and a physiologically acceptable vehicle or carrier.

294. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 292.
295. (Previously presented) The isolated cell of Claim 294, wherein said isolated cell is a hybridoma.
296. (Currently amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.
297. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 296 and a physiologically acceptable vehicle or carrier.
298. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 296.
299. (Previously presented) The isolated cell of Claim 298, wherein said isolated cell is a hybridoma.
300. (Previously presented) Antibody 7B11 (ATCC Accession No. HB-12195) or an antigen-binding fragment thereof.
301. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 300 and a physiologically acceptable vehicle or carrier.
302. (Previously presented) The hybridoma cell line deposited under ATCC Accession No. HB-12195.

303. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195).
304. (Previously presented) The antibody or antigen-binding fragment of Claim 303 wherein said antibody or fragment is a humanized immunoglobulin or antigen-binding fragment thereof comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195) and a human framework region.
305. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 303 and a physiologically acceptable vehicle or carrier.
306. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 303.
307. (Previously presented) The isolated cell of Claim 306, wherein said isolated cell is a hybridoma.
308. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
309. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

310. (Previously presented) The antibody or antigen-binding fragment of Claim 309, wherein said ligand is selected from the group consisting of RANTES and MCP-3.
311. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.
312. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
313. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
314. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
315. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
316. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

317. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 308 and a physiologically acceptable vehicle or carrier.
318. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 308.
319. (Previously presented) The isolated cell of Claim 318, wherein said isolated cell is a hybridoma.
320. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
321. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
322. (Previously presented) The antibody or antigen-binding fragment of Claim 321, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.
323. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.
324. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

325. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
326. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
327. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
328. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
329. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 320 and a physiologically acceptable vehicle or carrier.
330. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 320.
331. (Previously presented) The isolated cell of Claim 330, wherein said isolated cell is a hybridoma.
332. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid

sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

- 333. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
- 334. (Previously presented) The antibody or antigen-binding fragment of Claim 333, wherein said ligand is selected from the group consisting of RANTES, MCP-3, eotaxin, MCP-2 and MCP-4.
- 335. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
- 336. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
- 337. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
- 338. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 332 and a physiologically acceptable vehicle or carrier.
- 339. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 332.

340. (Previously presented) The isolated cell of Claim 339, wherein said isolated cell is a hybridoma.
341. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.
342. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
343. (Previously presented) The antibody or antigen-binding fragment of Claim 342, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.
344. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
345. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

346. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
347. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
348. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
349. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
350. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 341 and a physiologically acceptable vehicle or carrier.
351. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 341.
352. (Previously presented) The isolated cell of Claim 351, wherein said isolated cell is a hybridoma.

353. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
354. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.
355. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5. [[356.]]
356. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.